Role of Cod Liver Oil in Preventing Myocardial Infarction.
cod liver oil
myocardial infarction
prevention
primary prevention
supplementary medicine
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
accepted:
29
06
2021
entrez:
4
8
2021
pubmed:
5
8
2021
medline:
5
8
2021
Statut:
epublish
Résumé
Omega-3 fatty acids have for long been shown to reduce the incidence of cardiovascular (CV) diseases. Omega-3 fatty acids mainly exist in the form of eicosapentaenoic acid (EPA) and docosahexaenoic acid in fish oils. Cod liver oil is found to have a high concentration of these omega-3 fatty acids. This study aims to explore the benefits of using cod liver oil in reducing the incidence of myocardial infarction (MI) among at-risk patients. Method: This open-label placebo-controlled two-arm interventional study was conducted in the internal medicine and cardiology unit of tertiary care hospital between January 2018 to January 2021. During this period, 870 patients at risk of CV events were enrolled in the study after obtaining informed consent. The study group received 415 mg cod liver oil daily, in addition to their current treatment, in a bottle without label and the control group received no additional treatment to their standard treatment. Patients were followed up for 12 months or till the development of MI. Patients treated with cod liver oil had comparatively fewer incidences of MI; however, the difference was not significant (p-value: 0.09). Furthermore, the difference was non-significant for both fatal and non-fatal MI. The relative risk for total MI incidence was 0.70 (0.44-1.10). According to our study, adding cod liver oil to the diet does not play a major role in reducing the risk of MI. Further large-scale studies are needed to understand the role of cod liver oil in reducing the risk of CV events, including MI.
Identifiants
pubmed: 34345552
doi: 10.7759/cureus.16067
pmc: PMC8324067
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e16067Informations de copyright
Copyright © 2021, Mal et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lipids. 2003 Apr;38(4):343-52
pubmed: 12848278
Annu Rev Nutr. 2005;25:317-40
pubmed: 16011470
Am J Clin Nutr. 1997 Oct;66(4 Suppl):1020S-1031S
pubmed: 9322583
Arch Intern Med. 2001 Oct 8;161(18):2185-92
pubmed: 11575974
Cardiovasc Drugs Ther. 1997 Jul;11(3):485-91
pubmed: 9310278
JAMA. 2006 Oct 18;296(15):1885-99
pubmed: 17047219
Food Chem Toxicol. 2010 Nov;48(11):3093-7
pubmed: 20692313
Blood. 1993 Apr 1;81(7):1871-9
pubmed: 8461472
Prog Cardiovasc Dis. 2009 Sep-Oct;52(2):95-114
pubmed: 19732603
Circulation. 1999 May 11;99(18):2452-7
pubmed: 10318669
Eur J Epidemiol. 2012 Dec;27(12):891-4
pubmed: 23283593
Eur Heart J. 2008 Apr;29(7):932-40
pubmed: 18334475
J Am Coll Cardiol. 2007 Nov 27;50(22):2173-95
pubmed: 18036459
BMJ Open. 2017 Oct 13;7(10):e017471
pubmed: 29030414
N Engl J Med. 1986 Oct 2;315(14):841-6
pubmed: 3748103
Public Health Nutr. 2016 Feb;19(2):318-25
pubmed: 25882499
Prostaglandins. 1980 Dec;20(6):1021-31
pubmed: 7208950